Full Paper
to give the desired product as a pale yellow oil (660mg,
Table 3. Product [%] at 32 min for reactions of 4,7-dichloro-quinoline, 2-amino-6-
chloropurine and 1-fluoro-2,4-dinitrobenzene with anilines, varying the concentration
of TFA (0, 0.5, 1, 2.5, 5 and 10 equiv) in TFE at 258C.
89%). Rf =0.53 (DCM/MeOH 9:1); UV lmax (EtOH):
274 nm; IR (KBr): v˜ =2940, 2860, 2550, 1600, 1570 cmÀ1
;
1H NMR (500 MHz, CDCl3): d=1.14–1.18 (21H, m,
CH(CH3)2), 7.09 (1H, t, J=7.3 Hz, Ar-H), 7.21 (1H, brs,
NH), 7.32–7.35 (2H, m, Ar-H), 7.37 (1H, s, H-8), 7.53–7.57
(2H, m, Ar-H), 11.75 ppm (1H, brs, N9-H); 13C NMR
(125 MHz, CDCl3): d=11.3, 18.7, 100.8, 101.8, 120.7,
123.7, 129.3, 139.3, 140.9, 142.5, 153.2, 156.5, 184.8 ppm;
HRMS calcd for C22H30N5Si [M+H]+ 392.2270, found
392.2263.
Heteroaryl
substrate
Aniline
TFA equivalents
0
0
0.5
37
1
2.5
5
10
0
51
53
0
6
3
6-Cyclohexylmethoxy-7-methyl-2-(4’-sulfamoylanilino)-
7H-purine (12): The title compound was synthesised ac-
cording to the general procedure A using 6-cyclohexyl-
methoxy-2-fluoro-7-methyl-7H-purine (50mg, 0.19mmol),
sulfanilamide (65mg, 0.38mmol) and TFA (0.07mL,
0.95mmol) in TFE (4mL). The crude product was purified
by MPLC on silica (EtOAc/MeOH 9:1) to give a pale
brown powder (48mg, 61%). Rf =0.48 (EtOAc/MeOH
9:1); m.p. 252–2538C; UV lmax (EtOH): 292 nm; IR (neat
0
3
48
35
60
53
60
51
0
0
0
0
17
22
19
0
0
0
0
powder):
v ;
max =3373, 3313, 2922, 1569, 1504 cmÀ1
1H NMR (300 MHz, [D6]DMSO): d=0.95–1.80 (11H, m, H-
cyclo), 3.91 (3H, s, CH3), 4.33 (2H, d, J=5.4 Hz, OCH2),
7.11 (2H, s, NH2), 7.70 (2H, d, J=8.4 Hz, Ar-H), 7.97 (2H,
d, J=8.4 Hz, Ar-H), 8.19 (1H, s, H-8), 9.65 ppm (1H, s,
NH); 13C NMR (75 MHz, [D6]DMSO); d=25.6, 26.3, 29.6,
33.9, 37.1, 71.7, 108.7, 117.5, 126.8, 135.8, 144.8, 147.0,
155.1, 157.4, 162.9 ppm; MS (ES+) m/z 417 [M+H]+;
HRMS calcd for C19H25N6O3S [M+H]+ 417.1703, found
417.1704.
8[a]
11[a]
11[a]
0
0
9[a]
26[a]
73[a]
68[a]
4-(6-Amino-4-cyclohexylmethoxy-5-pyrimidin-2-ylami-
no)benzoic acid (14): The title compound was prepared
following general procedure A using 4-cyclohexyl-
[a] Yield [%] at 128 min.
methoxy-2-n-butylsulfonylpyrimidin-6-amine
(0.30g,
Caution! TFA and TFE should be handled with care. TFA causes
severe burns and TFE is irritating to the respiratory system and
skin and can seriously damage the eyes.
0.92mmol), 4-aminobenzoic acid (0.25g, 1.83mmol) and TFA
(0.36mL, 4.59mmol) in TFE (3mL). The system was cooled to RT
and concentrated under reduced pressure to yield an orange solid.
An aqueous 2m NaOH solution (20mL) was added to the residue
while stirring. After extraction with EtOAc (3ꢁ30mL), the aqueous
layer was acidified until pH<2 with a 4m HCl solution. A second
extraction with EtOAc (4ꢁ30mL) was performed on the aqueous
acidic phase. The organic fractions were combined, washed with
water (3ꢁ30mL) and dried over Na2SO4. After the solvent was
evaporated and the crude compound was recrystallized from
MeOH, the title compound was recovered as an off-white solid
(0.26g, 82%). Rf =0.27 (DCM/MeOH 95:5); m.p. 272–2758C; UV lmax
(EtOH): 302 nm; IR (neat powder): vmax =3514, 3404, 3105, 2932,
General procedure A
Typically, to a stirred suspension of the appropriate heteroaryl sub-
strate (1 equiv) and the aniline (2 equiv) in TFE ([heteroaryl sub-
strate]=0.1m) was added TFA (2.5 equiv) dropwise. The resulting
solution was heated at reflux for 24h under a nitrogen atmos-
phere. The solvent was removed in vacuo and the residue was re-
dissolved in EtOAc (10mL). The solution was washed with saturat-
ed sodium bicarbonate solution (3ꢁ10mL), and the aqueous ex-
tracts were combined and washed with EtOAc (10mL). The com-
bined organic layers were dried (MgSO4 or Na2SO4) and the solvent
was removed to give a residue that was purified as indicated for
each product. Four representative examples of this procedure are
given below with others to be found in Supporting Information.
2847, 1673, 1567, 1510 cmÀ1 1H NMR (300 MHz, [D6]DMSO): d=
;
0.95–1.29 (6H, m, H-cyclo), 1.68–1.79 (5H, m, H-cyclo), 4.01 (2H, d,
J=5.9 Hz, OCH2), 5.28 (1H, s, H-5), 6.43 (2H, brs, NH2), 7.78 (2H, d,
J=8.7 Hz, Ar-H), 7.88 (2H, d, J=8.7 Hz, Ar-H), 9.35 (1H, brs, NH),
12.45 ppm (1H, brs, OH); 13C NMR (75 MHz, [D6]DMSO): d=24.8,
25.7, 28.9, 36.6, 70.0, 78.4, 117.0, 129.5, 139.1, 145.2, 155.0, 158.6,
166.7, 169.6 ppm; MS (ES+) m/z 343.34 [M+H]+; HRMS calcd for
C18H23N4O3 [M+H]+ 343.1765, found 343.1770.
6-(2-(Triisopropylsilyl)ethynyl)-N-phenyl-9H-purin-2-amine
(4):
The title compound was synthesised according to general proce-
dure A using 2-fluoro-6-((triisopropylsilyl)ethynyl)-9H-purine (0.46g,
1.43mmol), aniline (260 mL, 2.86mmol) and TFA (551 mL, 7.15mmol)
in TFE (7mL). The crude material was purified by MPLC on silica
(DCM/MeOH 19:1) to give the desired product as a yellow oil/gum
(390mg, 1.00mmol, 70%). The title compound was also synthes-
ised following general procedure B for 30min using 2-fluoro-6-((trii-
sopropylsilyl) ethynyl)-9H-purine (600mg, 1.90mmol), aniline
(0.50mL, 3.80mmol) and TFA (0.7mL) in TFE (19mL). The crude
product was purified by MPLC on amine silica (DCM/MeOH 95:5)
8-Methyl-N-(4-phenoxyphenyl)-9H-purin-2-amine (28): The title
compound was synthesised following general procedure A using
2-fluoropurine intermediate (70mg, 0.46mmol) and 4-phenoxyani-
line (0.170g, 0.92mmol) were treated with TFA (177 mL, 2.30mmol)
in TFE (6mL). The crude product was purified by MPLC on silica
(DCM/MeOH 19:1) to afford a pale pink solid (0.101g, 75%). Rf =
0.39 (DCM/MeOH 19:1); m.p. 228–2318C; UV lmax (EtOH): 277 nm;
IR (neat powder): vmax =3454, 3253, 3194, 3044, 2924, 2161,
Chem. Eur. J. 2014, 20, 2311 – 2317
2316
ꢀ 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim